Case Studies

We own every client experience and its impact on results.

Fueled by a vision to advance life science services toward a healthier world, we put equal weight on how we partner with our clients to improve the lives of patients.

How do we do it?

Take a look at some of our client success stories:

Every Patient Matters

High-touch engagement helps patients overcome obstacles to result in a 95% compliance rate.

Learn More

Improve Adherence

Dedicated patient services coordinators and wraparound education help patients adhere to a complex orphan drug therapy.

Learn More

Rare Disease Launch

Optimized the launch of a first-to-market orphan therapy with complex access and adherence challenges.

Learn More

NEW CONTACT TEAM IN UNDER 7 DAYS

A sudden transfer of ownership for an immunotherapy product required access to a call center staffed with PharmDs. Our team had them covered in under 7 days.

Learn More

FDA APPROVES SMALL CLINICAL TRIAL

We supported a client to get FDA approvals for an ultra-rare therapy. Initially the small population was a concern.

Learn More

Share of Voice Matters

Dedicated field solutions team grew an under-promoted brand portfolio by an estimated $100M.

Learn More

ANTIBIOTIC ORDER REQUIRES PRECISION IN DELIVERY

A manufacturer of a generic antibiotic lands a government contract that requires precision delivery, resulting in monthly sales increase of 40%.

Learn More

WAC STRATEGIES

WAC pricing impacts performance across product life cycle.

Learn More

Pricing Matters

Holistic view of pricing maximizes revenue for a pharmaceutical manufacturer.

Learn More

CO-CREATING WITH PATIENTS

A client asked us to educate patients about a rare disease and therapy due to its complexity. We partner with patients to understand the true challenges and co-created material that resulted in 21% year-over-year growth.

Learn More

SPEED TO THERAPY

Reduced access barriers and simplified patient onboarding for faster therapy initiation.

Learn More

ACCOUNT STRATEGY PAYS OFF WITH A PBM

Client experienced significant revenue loss after brand was excluded from a national preferred drug list.

Learn More